KPV 10MG

Product information

Research mechanisms and models

KPV is described as the terminal tripeptide region of α-MSH, with a capped form discussed on this page. Research focuses on PepT1-mediated entry and NF-κB/MAPK-related inflammatory signaling. The source covers mouse colitis and delivery-system studies, antimicrobial assays, particulate-exposed keratinocytes, and lipid-related experiments in 3T3-L1 and HepG2 cells.

Limits of the findings

These are cell and animal observations, not established treatment effects. The page reports no completed human trials or long-term human safety evidence and distinguishes KPV's signaling research from BPC-157 tissue-repair research. It cautions that capped and uncapped forms have different masses and should not be treated as interchangeable experimental materials.

Specifications